Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 22;27(1):53.
doi: 10.1007/s11894-025-01002-5.

Resmetirom for Steatotic Liver Disease: Does Data Support Widespread Use?

Winston Dunn  1 , Naim Alkhouri  2
Affiliations
Review

Resmetirom for Steatotic Liver Disease: Does Data Support Widespread Use?

Winston Dunn et al. Curr Gastroenterol Rep. .

Abstract

Metabolic dysfunction-associated steatohepatitis with significant fibrosis is the aggressive form of steatotic liver disease that can progress to cirrhosis and its complications. Resmetirom is a liver-directed thyroid hormone receptor beta agonist that recently received accelerated approval by the FDA based on the results of the MAESTRO trial that demonstrated reasonable safety and efficacy in achieving both MASH resolution and fibrosis regression based on histological assessment. In this review, we discuss the resmetirom clinical development program, the use of noninvasive tests to select and monitor patients for treatment, and different aspects of the utility of resmetirom in the real world.

Keywords: MASH (Metabolic Dysfunction-Associated Steatohepatitis); MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease); Real-world data; Resmetirom; Thyroid hormone receptor beta agonist.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: The authors declare no competing interests. W.D has received grant/research support from 89bio, Gilead Sciences, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, Novo Nordisk; reports speaker’s fees from Gilead Sciences and Madrigal Pharmaceuticals; and reports consulting for Ipsen and Novo Nordisk. N.A. has received grant/research support from 89bio, Akero Therapeutics, Arbutus Biopharma, AstraZeneca, BioAge, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Galectin Therapeutics, Genentech, Gilead Sciences, Hepagene Therapeutics, Intercept Pharmaceuticals, Inventiva Pharma, Ionis Pharmaceuticals, Ipsen, Lilly, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, PharmaIN, Poxel, Regeneron, Viking Therapeutics, and Zydus Pharmaceuticals; reports speaker’s fees from AbbVie, AstraZeneca, Echosens, Gilead Sciences, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, and Perspectum; and reports consulting for 89bio, AbbVie, Akero, Boehringer Ingelheim, Echosens, Fibronostics, Gilead Sciences, HistoIndex, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, and Regeneron.

Similar articles

See all similar articles

Cited by

References

    1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–86. - PubMed
    1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335–47. - PubMed
    1. Diaz LA, Lazarus JV, Fuentes-Lopez E, Idalsoaga F, Ayares G, Desaleng H, Danpanichkul P, et al. Disparities in steatosis prevalence in the united States by race or ethnicity according to the 2023 criteria. Commun Med (Lond). 2024;4:219. - PubMed
    1. Le P, Tatar M, Dasarathy S, Alkhouri N, Herman WH, Taksler GB, Deshpande A, et al. Estimated burden of metabolic Dysfunction-Associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025;8:e2454707. - PubMed - PMC
    1. Simon TG, Roelstraete B, Khalili H, Hagstrom H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70:1375–82. - PubMed

Substances

LinkOut - more resources